NCT02083861

Brief Summary

The purpose of this study is to measure the effectiveness of a wearable therapeutic ultrasound device in patients with stage I and stage II knee osteoarthritis. The ability of the device to reduce pain, increase mobility, increase range of motion and muscle strength of the affected leg, and improve quality of life in patients with knee osteoarthritis will be evaluated.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
93

participants targeted

Target at P50-P75 for not_applicable knee-osteoarthritis

Timeline
Completed

Started Mar 2014

Shorter than P25 for not_applicable knee-osteoarthritis

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2014

Completed
6 days until next milestone

First Submitted

Initial submission to the registry

March 7, 2014

Completed
4 days until next milestone

First Posted

Study publicly available on registry

March 11, 2014

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2014

Completed
3.6 years until next milestone

Results Posted

Study results publicly available

May 7, 2018

Completed
Last Updated

May 7, 2018

Status Verified

April 1, 2018

Enrollment Period

7 months

First QC Date

March 7, 2014

Results QC Date

February 27, 2017

Last Update Submit

April 2, 2018

Conditions

Keywords

osteoarthritisarthritismusculoskeletalconnective tissue diseaseultrasoundpainmobilityheatstrengthZetrOZLITUSSamgrade 1grade 2

Outcome Measures

Primary Outcomes (1)

  • Pain on the Numeric Rating Scale (NRS) Change From Baseline to Study Conclusion

    The numeric rating scale (NRS) was used to assess change in pain from baseline to study conclusion. NRS range from 0-10 with 0 being no pain and 10 the worst pain possible.

    Baseline, Week 6

Secondary Outcomes (3)

  • Quality of Life (WOMAC) Change From Baseline

    Baseline, Week 6

  • Range of Motion Change From Baseline in Treated Knee

    Baseline, Week 6

  • Muscle Strength Change From Baseline in Treated Knee

    Baseline to 6 Weeks

Study Arms (2)

Active ultrasound device

EXPERIMENTAL

Patients receive treatment from the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The active device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.

Device: Sam Ultrasonic Diathermy Device

Placebo ultrasound device

PLACEBO COMPARATOR

Patients wear the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The placebo device appears and operates identically to the active device except that it does not emit ultrasound.

Device: Sam Ultrasonic Diathermy Device

Interventions

Patients apply the Sam Ultrasonic Diathermy Device daily for 4 hours of continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.

Also known as: ZetrOZ ultrasound device, wearable ultrasound device, long duration ultrasound, LITUS device, long duration low intensity device
Active ultrasound devicePlacebo ultrasound device

Eligibility Criteria

Age35 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Physician-diagnosed mild to moderate knee osteoarthritis (OARSI atlas grades 1-2) based on fixed-flexion x-ray radiological findings for osteophytes and joint space narrowing within the past 12 months
  • Fulfill the American College of Rheumatology clinical and radiological diagnostic criteria for knee OA
  • years of age
  • Report a frequent pain score between 3-7 (NRS range: 0-10) during the week preceding enrollment
  • Report that knee pain negatively affects quality of life
  • Willing not to use any cream, gel, or topical solution during the administration of treatment other than the approved ultrasound gel provided to the subject at the initiation of the study
  • Deemed appropriate by their physician or by the study site physician to participate

You may not qualify if:

  • Cannot successfully demonstrate the ability to put on and take off the device
  • Display any condition which, in the judgment of the investigator, would make participation in the study unacceptable, including, but not limited to, the subject's ability to understand and follow instructions.
  • Have severe OA or have little to no cartilage in the knee
  • Have knee replacement, other surgical intervention, or hyaluronidase injection in the affected knee in the past 6 months
  • Are non-ambulatory
  • Participated in a clinical trial for an investigational drug and/or agent within 30 days prior to screening
  • Modify their medications during the course of the study (medications and doses must remain constant throughout the study)
  • Currently taking steroids
  • Have contraindication to radiograph
  • Have a secondary cause of arthritis (metabolic or inflammatory)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medical Pain Consultants

Dryden, New York, 13053, United States

Location

Related Publications (1)

  • Draper DO, Klyve D, Ortiz R, Best TM. Effect of low-intensity long-duration ultrasound on the symptomatic relief of knee osteoarthritis: a randomized, placebo-controlled double-blind study. J Orthop Surg Res. 2018 Oct 16;13(1):257. doi: 10.1186/s13018-018-0965-0.

MeSH Terms

Conditions

Osteoarthritis, KneeOsteoarthritisArthritisConnective Tissue DiseasesPainLymphoma, Follicular

Condition Hierarchy (Ancestors)

Joint DiseasesMusculoskeletal DiseasesRheumatic DiseasesSkin and Connective Tissue DiseasesNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsLymphoma, Non-HodgkinLymphomaNeoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Limitations and Caveats

Small number of patients enrolled in range of motion and strength study may have limited statistical analysis. Future studies should include larger sample sizes.

Results Point of Contact

Title
Dr. Ralph Ortiz
Organization
Pain Management Associates

Study Officials

  • Ralph Ortiz, D.O., MPH

    Medical Pain Consultants

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 7, 2014

First Posted

March 11, 2014

Study Start

March 1, 2014

Primary Completion

October 1, 2014

Study Completion

October 1, 2014

Last Updated

May 7, 2018

Results First Posted

May 7, 2018

Record last verified: 2018-04

Locations